Schrodinger, Inc. (SDGR)

Over the past six months, Schrödinger, Inc.'s stock price has been impacted by several key events, including a significant decrease of 45.06% over the last 12 months. In Q1 2026, revenue exceeded expectations, but statutory losses widened, leading to adjusted revenue and loss forecasts. The announced acquisition of Ajax Therapeutics by Lilly, in which Schrödinger held an equity stake, was highlighted as a validation of Schrödinger's platform. The upcoming launch of "Bunsen" is drawing early excitement. The company is accelerating its transition to a hosted software licensing model, impacting near-term software revenue recognition but expected to lead to durable ACV growth. Analysts have adjusted their price targets downwards, reflecting concerns about near-term revenue pressure. Schrödinger shares fell after the company filed a proxy seeking shareholder approval to add 3 million shares to its 2022 Equity Incentive Plan.

Based on the available information, there is no explicit data indicating demand seasonality for Schrödinger, Inc.'s products and services. The search results refer to "seasonality" in the context of stock performance and returns, focusing on mean and median monthly returns for the SDGR stock to identify potential price movements.

Schrödinger, Inc. is an international scientific software and biotechnology company specializing in computational tools and software for drug discovery and materials science, operating within various sectors including Software, Life Sciences, and Healthcare. They offer an advanced computational platform for drug discovery and materials science, along with software tools for molecular dynamics simulations, free energy calculations, and virtual screening. Key products include Maestro, LiveDesign, FEP+, and a Materials Science Suite. They also provide solutions for Biologics Discovery and consulting services, collaborating with industry partners.

Schrödinger, Inc. has a global footprint with over a dozen offices and is headquartered in New York, New York. It maintains offices in other U.S. cities including Cambridge, Framingham, Portland, and San Diego. Internationally, Schrödinger has a presence in Europe, with offices in Mannheim and München, Germany, and Reading, UK, as well as in Asia, specifically Japan.

Schrödinger, Inc. has received positive recognition in previous years, including being recognized by Newsweek as No. 1 in Pharmaceuticals and Biotech in 2022. The company has emphasized its commitment to corporate sustainability, including environmental sustainability efforts and responsible AI, maintaining a formal AI Use Policy. The company's stock has experienced significant volatility, which is considered a minor risk and could indirectly affect investor perception and, to some extent, overall brand sentiment.

Schrödinger, Inc. has a diverse ownership structure, with approximately 79.05% of the stock held by institutions, 21.00% by insiders, and 46.01% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Bill & Melinda Gates Foundation Trust, and Vanguard Group Inc. Notable individual owners include Bill Gates and David E. Shaw. Insiders have sold more company stock than they have bought in the past three months.